This event aims to accelerate:
- The development of new and repurposed medicines for COVID-19 therapeutics, i.e. medicines specifically developed for an indication in treatment of COVID-19, at all stages of COVID-19 disease;
- The development of medicines used to treat the symptoms of COVID-19;
- The production of disposable materials (e.g. single use systems), ingredients and raw materials required for the manufacture of medicinal products.
It also aims to mobilise the EU pharma manufacturing capacity for the production of medicines to treat or prevent COVID-19.
The event is organised by the European Commission in partnership with the Council of European BioRegions (CEBR), the European Cluster Alliance (ECA) and the European Cluster Collaboration Platform.
Companies interested in participating in the event must complete the registration form by 18 November 2021 (23h59 CEST).
